RxDoctor Payments Data

Muhammad Irfan, MD

Psychiatry · West Chester, PANPI 1902851983

Payments from drug & device makers

$2,476in general payments, 2019–2025

Across 108 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$572
  • Otsuka America Pharmaceutical, Inc.$416
  • Takeda Pharmaceuticals U.S.A., Inc.$159
  • Johnson & Johnson$141
  • Vanda Pharmaceuticals Inc.$136
  • E.r. Squibb & Sons, L.L.C.$132
  • plus $920 from 19 others

What the payments were for

  • Food & beverage$2,37096%
  • Education$1064%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,476 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$3,447
Medicare patients
30
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate24$85,492
Abilify MaintenaAripiprazole16$43,269
Clozapine52$3,407
Divalproex Sodium ErDivalproex Sodium44$1,741
RemeronMirtazapine12$1,698
Duloxetine Hcl40$1,351
Quetiapine Fumarate142$1,297
Quetiapine Fumarate ErQuetiapine Fumarate19$1,131
Bupropion XlBupropion Hcl42$1,117
Buspirone Hcl75$1,116
Venlafaxine Hcl ErVenlafaxine Hcl47$1,113
Vilazodone Hcl11$1,064
Aripiprazole55$1,027
Escitalopram Oxalate90$899
Fluoxetine Hcl86$895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$141$85,49224 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$416$43,26916 claims
Almatica Pharma LLCSertraline Hcl$36$43970 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →